Roche has launched the cobas Mass Spec, a groundbreaking device for mass spectrometry that has received CE Mark approval. This innovative solution will provide over sixty analytical tests, enhancing patient care by enabling earlier detection of therapeutic responses, particularly in breast cancer patients undergoing hormonal therapy. The technology promotes automation and sustainability in laboratory workflows, aligning with Roche's strategic integration of clinical chemistry and immunochemistry testing.
